Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2− advanced breast cancer
- Published on 03/28/2024
- Reading time: 4 min.
Juan Hong a,* , Tujia Chen b,* , Lihui Ouyang c , Ning Du a , Anna Li a , Zhongqi Zhou d , HaiLing Zhang d , Zhengzheng Xia a,* & Jun Meng a,*
a Department of Pharmacy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China
b Department of Pharmacy, Boai Hospital of Zhongshan, Zhongshan, China
c Department of Pharmacy, The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, Changsha, China
d School of Pharmacy, Guangdong Medical University, Dongguan, China
CONTACT Zhengzheng Xia mailto:xiazhengzheng@cicams-sz.org.cn
Jun Meng mailto:meng@cicams-sz.org.cn Department of Pharmacy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen
518116, China
Abstract
Objectives CDK4/6 inhibitors dalpiciclib and abemaciclib have been approved by the Chinese National Medical Products Administration as first-line treatment for postmenopausal females with hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2−) advanced breast cancer (ABC). We aimed to assess the cost-effectiveness of dalpiciclib plus letrozole/anastrozole (non-steroidal aromatase inhibitor [NSAI]) compared with abemaciclib...
To continue reading this article in Full-Text...
Peer-Reviewed Journals A-Z
Search | Advanced search
Get the latest news in Oncology
Receive our newsletter to stay up to date with the latest news in Oncology
